Document Actions

You are here: Home Faculty Professors Voll


Prof. Dr.
Reinhard E. Voll

Department of Rheumatology and Clinical Immunology
Medical Director
Phone: 0049-761-270-34480


  • 1993-1994 Postdoctoral training, Max-Planck-Society, Clinical Research Units for Rheumatology (Section Prof. Dr. F. Emmrich) at the University of Erlangen-Nürnberg, Germany
  • 1996-1998 Postdoctoral fellowship of the DFG, Laboratory of Dr. Sankar Ghosh,  section of immunobiology, Howard Hughes Medical Institute, Yale University, School of Medicine, New Haven, CT, USA
  • 2003-2009 Head of the Research Group 2 of the Interdisciplinary Center of Clinical Research, University Hospital Erlangen
  • 2005-2010 Senior Physician, University Hospital Erlangen (Dept. Internal Medicine 3, Rheumatology and Immunology)
  • Since 2010 Full Professor (W3) and Medical Director, Department of Rheumatology and Clinical Immunology, Medical Center – University of Freiburg

Focus of research

  • The role of apoptotic cell death in the pathogenesis of systemic lupus erythematosus (SLE)
  • Treatment of antibody-mediated diseases by targeting plasma cells
  • The role of sodium chloride in the pathogenesis of inflammatory diseases

Selected publications

  • Alexander T, Sarfert R, ... Hiepe F, Voll RE. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015; 74(7):1474-8.
  • Sehnert B, Burkhardt H, Wessels JT, Schröder A, May MJ, Vestweber D, Zwerina J, Warnatz K, Nimmerjahn F, Schett G, Dübel S, Voll RE. NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseases. Proc Natl Acad Sci USA. 2013; 110(41):16556-16561.
  • Fürnrohr BG, Wach S, ... Harley JB, Voll RE. Polymorphisms in the Hsp70 gene locus are genetically associated with systemic lupus erythematosus. Ann Rheum Dis. 2010; 69(11):1983-9.
  • Urbonaviciute V, Fürnrohr BG, ... Herrmann M, Voll RE. Induction of infl ammatory and immune responses by HMGB1-nucleosome complexes – implications for the pathogenesis of SLE; J Exp Med. 2008; 205(13):3007-18.
  • Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008; 14(7):748-55.